Page 332 - 北京京煤集团总医院第十届·2022学术年会论文集

北京京煤集团总医院 第十届·2022 学术年会论文集

group and contemporaneous 40 subjects undergoing the healthy physical examination as the control

group. According to the stage standard by international federation of obstetrics and gynecolog

(FIGO), the patients with ovarian cancer patients were divided into stage I + II group (n=25), stage
III + IV group (n=15); according to the degree of tumor differentiation, the patients with ovarian

cancer were divided into the low differentiation group (n=12), medium differentiation group (n=19)
and high differentiation group (n=9). The levels of CA125 and PLR were comparedin among the

groups, and the changes of CA125 and PLR levels in different FIGO stages and differentiation levels

of ovarian cancer were analyzed. The area under the receiver operating characteristrc (ROC) curve

(AUC) was used to analyze the value of each parameter in the diagnosis of ovarian cancer. Results

The levels of CA125 and PLR in benign ovarian tumor group and ovarian cancer group were

evidently higher than those in the conter group (P<0.05),moreover the ovarian cancer group was

evidently higher than that the benign ovarian tumor group (P<0.05); the levels of CA125 and PLR

in the stage Ⅲ + Ⅳ group were evidently higher than those in the stage Ⅰ + Ⅱ group (P<0.05); the

levels of CA125 and PLR in the low differentiated group and medium differentiated group were

evidently higher than that of the highly differentiated group (P<0.05), moreover the low

differentiation group was evidently higher than the medium differentiated group (P<0.05); The
AUC values of CA125 and PLR for diagnosis of ovarian cancer were 0.873 and 0.832, respectively.

Conclusion The levels of CA125 and PLR in the patients with ovarian cancer are increased
significantly, and the more serious the development of ovarian cancer, the higher the levels of

CA125 and PLR, moreover CA125 and PLR have certain diagnostic efficacy in the early diagnosis

of ovarian cancer.

Key words: Ovarian cancer; carbohydrate antigen 125; platelet to lymphocyte ratio; diagnostic

value

卵巢癌是临床上常见的一种妇科恶性肿瘤，该疾病是导致全球范围内妇女相关癌症死亡

[3]
的第五大原因 [1,2] 。有研究表明 ，全球每年新增卵巢癌病例约 24 万，死亡病例约 15 万，且
[3]
卵巢癌患者 5 年总生存率低于 50% 。而目前，临床上还未发现快速、有效、便捷的卵巢癌
筛选方法。研究表明，卵巢癌的发生发展与细胞因子密切相关，糖类抗原 125（CA125）是

临床上常用的肿瘤标记物，在恶性肿瘤患者中其水平明显上升 [4-6] 。另外，血小板与淋巴细

胞比值（PLR）可反映机体内血小板及淋巴细胞水平变化，显示机体免疫功能及炎性反应程

度。为明确卵巢癌的早期诊断方式，本研究旨在探讨 CA125 与 PLR 在卵巢癌中的诊断价值

- 327 -